Pharmaceutical

Plocabulin by Pharma Mar for Biliary Tumor: Likelihood ...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Plocabulin by Pharma Mar for Adenocarcinoma: Likelihood...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Plocabulin by Pharma Mar for Peritoneal Cancer: Likelih...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Plocabulin by Pharma Mar for Epithelial Ovarian Cancer:...

Nov 16, 2023

Plocabulin is under clinical development by Pharma Mar and currently in Phase I ...

Pembrolizumab by Merck for Sezary Syndrome: Likelihood ...

Nov 16, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase II f...

Pembrolizumab by Merck for Mycosis Fungoides: Likelihoo...

Nov 16, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase II f...

Gedeptin by GeoVax Labs for Nasopharyngeal Cancer: Like...

Nov 16, 2023

Gedeptin is under clinical development by GeoVax Labs and currently in Phase II ...

Rimegepant sulfate ODT by Pfizer for Rhinosinusitis: Li...

Nov 16, 2023

Rimegepant sulfate ODT is under clinical development by Pfizer and currently in ...

ATX-304 by Amplifier TX for Cardiometabolic Disease: Li...

Nov 16, 2023

ATX-304 is under clinical development by Amplifier TX and currently in Phase I f...

Vamorolone by ReveraGen BioPharma for Becker Muscular D...

Nov 16, 2023

Vamorolone is under clinical development by ReveraGen BioPharma and currently in...

STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward

STAT+: After four patients died of gene therapy, Astell...

Nov 15, 2023

Astellas says its gene therapy study, halted when four children with a rare diso...

FDA grants approval for first time to a home test for chlamydia and gonorrhea

FDA grants approval for first time to a home test for c...

Nov 15, 2023

The FDA granted marketing approval to a home test for chlamydia and gonorrhea on...

STAT+: House panel passes PBM reforms, ratcheting up chance for passage

STAT+: House panel passes PBM reforms, ratcheting up ch...

Nov 15, 2023

Panels in both the House and Senate have now passed restrictions to drug middlem...

STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds

STAT+: More drug and device patents were invalidated fo...

Nov 15, 2023

The patents on medicines and devices approved by the FDA were more frequently in...

STAT+: FDA’s latest reorganization puts a new emphasis on its investigations

STAT+: FDA’s latest reorganization puts a new emphasis ...

Nov 15, 2023

The FDA is in the final stages of cementing sweeping changes to the Office of Re...

STAT+: House moves to limit so-called gain-of-function research

STAT+: House moves to limit so-called gain-of-function ...

Nov 15, 2023

House lawmakers approved an amendment that, if it advances, would ban controvers...